Entering text into the input field will update the search result below

Nymox stock rises 8% as it files for FDA approval of drug treating enlarged prostate

Mar. 03, 2022 1:09 PM ETNymox Pharmaceutical Corporation (NYMXF)By: Ravikash, SA News Editor5 Comments

Headquarters of US Food and Drug Administration (FDA)

Grandbrothers/iStock Editorial via Getty Images

  • Nymox Pharmaceutical (NYMX +7.8%) submitted a new drug application (NDA) to the FDA for Fexapotide Triflutate to treat men with benign prostatic hyperplasia (BPH).
  • BPH also called prostate gland enlargement can cause uncomfortable urinary symptoms and

Recommended For You

Comments (5)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

sidnal5 profile picture
Competition has arisen from focused ultra sound.
Stan Piland profile picture
@sidnal5 Technically challenging, expensive, invasive, painful, and requires anesthesia. No chance any patient or doc would choose HIFU before FT.
Stan Piland profile picture
Finally! This is a transformative drug for treatment of enlarged prostate, can easily be a $10B+ drug once approved in all markets.
coffeedoc1 profile picture
@Stan Piland Hopefully they can stay out of their own way and find a good experienced partner to help bring this to market.
Stan Piland profile picture
@coffeedoc1 Agreed! Estimated 8.5M actively managed patients in the US and 13M in Europe. Plus 60M in APAC, which isn't in my estimates. Other drugs are all off patent, so I don't think they would have much trouble finding a partner. Also, FT is really inexpensive to manufacture, so they could likely get a very generous royalty.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.